Health Condition 1: J189- Pneumonia, unspecified organism
Conditions
Interventions
Intervention1: PENTOXIFYLLINE SUPPLEMENTATION ALONG WITH STANDARD TREATMENT: In the experimental group, pentoxifylline will be given in the dose of 400 mg twice daily enterally within 24 hours of rand
Sponsors
SARANDEV A T V
Eligibility
Inclusion criteria
Inclusion criteria: 1)At least one acute clinical sign compatible with pneumonia (dyspnea, cough, purulent sputum, crackles) 2)Infiltrate on chest X-ray or CT scan suggestive of pneumonia 3)Diagnosis of CAP at or during the 48 hours post-hospital admission. 4)Informed consent signed by the patient, his/her legally authorized representative.
Exclusion criteria
Exclusion criteria: 1)Patient on invasive mechanical ventilation. 2)Patients with creatinine clearance less than 30 ml per minute 3)Patient on vasopressors at the time of inclusion 4)Any contraindications to the study drug 5)Patient requiring corticosteroids (except for nebulized corticosteroids) for any reason. 6)Patient treated with antibiotics for more than 7 days prior to admission. 7)Suspicion of aspiration or heath care associated pneumonia. 8)Active tuberculosis 9)On immunosuppressive therapy or malignancy 10)Pregnancy or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to overall clinical stability (TCS) defined as temperature less than or equall to 37·8 degree celsius, heart rate below 100 beats per minute, respiratory rate below 24 breaths per minute, arterial oxygen saturation of 90 percentage or higher on room air, systolic blood pressure of 90 mm Hg or higher, and baseline mental status. TCS is defined as the first day after the starting of study drug all the 5 vital signs fulfill the above criteria on same day and eating and mental status are stable. Timepoint: Over 7 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the change in inflammatory markers in terms of change in serum CRP and TNF alpha level between the groups. To evaluate the length of hospital stay (LOS) between the groups. To evaluate the time to individual vital sign stability between the groups. To determine the adverse effects in both the groups.Timepoint: Over the period of study | — |
Countries
India
Contacts
Public ContactDR DHRITI SUNDAR DAS
AIIMS BHUBANESWAR
Outcome results
None listed